Skip to main content

Aventis Subscribes to Gene Logic Custom Database

NEW YORK, Dec. 13 – Aventis has subscribed to a selection of samples in Gene Logic’s database, Gene Logic said Thursday.

Under the terms of the deal, Aventis will have access to samples culled from Gene Logic’s BioExpress database. The BioExpress database contains gene expression information for normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines for use in drug target identification.

Gene Logic said the deal for its CustomSuite, a customized database product, would give Aventis data directly applicable to the pharmaceutical company’s drug development projects.

In addition, Gene Logic will generate data for Aventis based on samples it provides to Gene Logic.

Gene Logic did not disclose the financial terms of the deal, its first with Aventis.

Aventis Pharmaceuticals is the U.S. division of Aventis Pharma of Frankfurt.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.